These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32902291)

  • 41. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
    Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S
    J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tissue-Specific Delivery of Oligonucleotides.
    Xia X; Pollock N; Zhou J; Rossi J
    Methods Mol Biol; 2019; 2036():17-50. PubMed ID: 31410789
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems.
    Mirzaei S; Mahabady MK; Zabolian A; Abbaspour A; Fallahzadeh P; Noori M; Hashemi F; Hushmandi K; Daneshi S; Kumar AP; Aref AR; Samarghandian S; Makvandi P; Khan H; Hamblin MR; Ashrafizadeh M; Zarrabi A
    Life Sci; 2021 Jun; 275():119368. PubMed ID: 33741417
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Critical issues in delivery of RNAi therapeutics in vivo.
    Rivera S; Yuan F
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1279-91. PubMed ID: 22201583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic siRNA delivery to tumors by cell-penetrating α-helical polypeptide-based metastable nanoparticles.
    Liu Y; Song Z; Zheng N; Nagasaka K; Yin L; Cheng J
    Nanoscale; 2018 Aug; 10(32):15339-15349. PubMed ID: 30070662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HOTAIR inhibits the proliferation of glioblastoma cells by targeting miR-219.
    Li H; Guan C
    Cancer Biomark; 2020; 28(1):41-47. PubMed ID: 32176624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. "Clicking" Gene Therapeutics: A Successful Union of Chemistry and Biomedicine for New Solutions.
    Astakhova K; Ray R; Taskova M; Uhd J; Carstens A; Morris K
    Mol Pharm; 2018 Aug; 15(8):2892-2899. PubMed ID: 29300491
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting Promoter-Associated Noncoding RNA In Vivo.
    Civenni G
    Methods Mol Biol; 2017; 1543():259-270. PubMed ID: 28349433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MicroRNA-Based Drugs for Brain Tumors.
    Anthiya S; Griveau A; Loussouarn C; Baril P; Garnett M; Issartel JP; Garcion E
    Trends Cancer; 2018 Mar; 4(3):222-238. PubMed ID: 29506672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation.
    Rong X; Huang B; Qiu S; Li X; He L; Peng Y
    Oncotarget; 2016 Dec; 7(51):83976-83986. PubMed ID: 27824617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases.
    Germain ND; Chung WK; Sarmiere PD
    Mol Aspects Med; 2023 Jun; 91():101148. PubMed ID: 36257857
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
    Liu Y; Xu N; Liu B; Huang Y; Zeng H; Yang Z; He Z; Guo H
    Oncotarget; 2016 Jul; 7(28):43835-43851. PubMed ID: 27270310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Micelleplexes as nucleic acid delivery systems for cancer-targeted therapies.
    Pereira-Silva M; Jarak I; Alvarez-Lorenzo C; Concheiro A; Santos AC; Veiga F; Figueiras A
    J Control Release; 2020 Jul; 323():442-462. PubMed ID: 32353488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells.
    Lou B; Connor K; Sweeney K; Miller IS; O'Farrell A; Ruiz-Hernandez E; Murray DM; Duffy GP; Wolfe A; Mastrobattista E; Byrne AT; Hennink WE
    Drug Deliv Transl Res; 2019 Jun; 9(3):679-693. PubMed ID: 30972664
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer.
    Yin T; Wang L; Yin L; Zhou J; Huo M
    Biomaterials; 2015 Aug; 61():10-25. PubMed ID: 25996409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.
    Tseng JH; Chen CY; Chen PC; Hsiao SH; Fan CC; Liang YC; Chen CP
    Oncotarget; 2017 Feb; 8(9):14666-14679. PubMed ID: 28108734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities.
    Thanki K; Blum KG; Thakur A; Rose F; Foged C
    Ther Deliv; 2018 Oct; 9(10):731-749. PubMed ID: 30277138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polyethylenimines for siRNA and miRNA delivery in vivo.
    Höbel S; Aigner A
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2013; 5(5):484-501. PubMed ID: 23720168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic face of RNAi: in vivo challenges.
    Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S
    Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multifunctional hybrid nanoconjugates for efficient in vivo delivery of immunomodulating oligonucleotides and enhanced antitumor immunity.
    Kim JH; Noh YW; Heo MB; Cho MY; Lim YT
    Angew Chem Int Ed Engl; 2012 Sep; 51(38):9670-3. PubMed ID: 22915476
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.